Loading company…
Seamless Therapeutics develops a recombinase-based gene editing platform for severe diseases.
Founded in Dresden in 2022, Seamless Therapeutics develops gene editing tools based on a recombinase platform. Its technology is designed to target locations across the genome to address severe conditions. The company was founded by Prof. Dr. Frank Buchholz, Anne-K. Heninger and Felix Lansing. It raised USD 12.5 million in seed funding in July 2022, co-led by Wellington Partners and Forbion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in